Cytek Biosciences Stock
Cytek Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Wenbin Jiang
- Employees
- 682
- Market cap
- $682 M
- IPO
- 23/07/2021
- Web
- cytekbio.com
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell…
Cytek Biosciences stock: price history
1D
-3.0%
1W
-3.3%
1M
+6.5%
6M
+13.9%
YTD
+4.0%
1Y
+30.6%
2Y
-2.1%
5Y
-78.2%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~73% stronger price swings than usual
Cytek Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Cytek Biosciences offers specialized cell analysis solutions used in biomedical research and clinical settings. The product portfolio comprises state-of-the-art flow cytometers such as the Aurora and Northern Lights systems that use spectral technology to determine complex fluorescence profiles of cells. These hardware components are complemented by specialized software called SpectroFlo as well as automated sample processing systems to optimize laboratory workflows. A key component of the business model is the provision of consumables, particularly specific reagents and immunoprofiling kits that are necessary for operating the analysis instruments. The company distributes its solutions globally through a combined model of direct sales and distributors in various regions such as North America, Europe, and Asia.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Cytek Biosciences
Analyst assessment of Cytek Biosciences
PRICE TARGET LOW
US$4.75
CONSENSUS
US$4.88
MEDIAN
US$4.88
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
3
BUY
1
HOLD
1
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 13/05/2026
Cytek Biosciences stock metrics
P/E
-8.43
P/B
2.11
EV/EBITDA
-23.39
RETURN ON EQUITY
-3.8%
NET MARGIN
-25.3%
DEBT/EQUITY
0.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.5%
FLOAT SHARES
118,955,632
AVG. DAILY VOLUME (30D)
1,515,193
Insider transactions (SEC)
McCombe William D.
McCombe William D.
McCombe William D.
McCombe William D.
McCombe William D.
Institutional holders
Comparable stocks
Frequently asked questions about Cytek Biosciences stock
What does Cytek Biosciences do?
Cytek Biosciences, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Wenbin Jiang, the company employs around 682 people.
The IPO was on 23/07/2021; the stock trades on NASDAQ under the ticker CTKB.
What do analysts say about Cytek Biosciences stock?
5 analysts rate the stock, the consensus is Buy (as of 13/05/2026).
The average price target is US$4.88, ranging from US$4.75 to US$5.00, with a median of US$4.88.
This is an external assessment, not a statement by Market Jury.
When does Cytek Biosciences report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 73% stronger than usual.
Does Cytek Biosciences pay a dividend?
No, Cytek Biosciences currently does not pay a dividend.
Which stocks are comparable to Cytek Biosciences?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Cytek Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cytek Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.